Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 8:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 35,409 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Newly Diagnosed Glioblastoma Multiforme
Interventions: Lapatinib/Temozolomide/radiation; Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: SNUG01; Drug
Lead sponsor: SineuGene Therapeutics Co., Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Opioid Use Disorder
Interventions: RMIST; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions: Quadrivalent VLP Vaccine, Fluarix Quadrivalent® Comparator Vaccine; Biological
Lead sponsor: Medicago; Industry
Eligibility: 65 Years and older
Enrollment: 12,794 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 50
States / cities: Mobile, Alabama • Tempe, Arizona • Banning, California + 42 more

Conditions: Healthy Volunteers
Interventions: BMS-986325, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy
Interventions: PF-04958242 capsule, PF-04958242 oral solution; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Surgical Wound Infection
Interventions: Aquacel Ag Surgical Dressing, Single-Use Negative Pressure Wound Therapy (PICO); Device
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non Small Cell Lung Carcinoma
Interventions: AZD6244, Erlotinib, AZD6244 + Erlotinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 5
States / cities: Davis, California • Los Angeles, California • South Pasadena, California + 2 more

Conditions: Prostate Cancer
Interventions: Tesetaxel; Drug
Lead sponsor: Genta Incorporated; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 4
States / cities: Ann Arbor, Michigan • New Brunswick, New Jersey • New York, New York + 1 more

Conditions: Ovarian Cancer
Interventions: Pembrolizumab, Paclitaxel; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 3
States / cities: Tampa, Florida • Durham, North Carolina • Richmond, Virginia

Conditions: Migraine
Interventions: Galcanezumab, Erenumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Los Angeles, California • Newport Beach, California • Waterbury, Connecticut

Conditions: Healthy
Interventions: Low Dose Regular insulin, High Dose Regular insulin, 0.9% Saline; Drug · Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 36 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Depression in Adolescence
Interventions: MoodRing App, Usual Care; Device · Other
Lead sponsor: Ana Radovic; Other
Eligibility: 12 Years to 18 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sickle Cell Disease
Interventions: Brief Cognitive-Behavioral Pain Management Training; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 8 Years to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Spinal Cord Stimulator Trial Period, Neuromodulation Trial Period, SCS Trial Period
Interventions: external securement of scs leads during the scs trial period; Procedure
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Healthy Volunteers
Interventions: TAK-020, TAK-020 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Acute Myocardial Infarction
Interventions: Post conditioning, Usual Care for STEMI; Procedure
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: H Pylori Infection, H Pylori Gastritis, Gastric Cancer
Interventions: PYTEST® 14C-Urea Breath Test, VOQUEZNA® Triple Pak®; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 430 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Dental Caries
Interventions: silver diamine fluoride, 38%, Sodium fluoride gel, 5000 PPM; Device
Lead sponsor: Texas A & M University Baylor College Of Dentistry; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Small Cell Lung Carcinoma
Interventions: Tarlatamab, Pembrolizumab, CRS Mitigation Strategies; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 15
States / cities: Duarte, California • New Haven, Connecticut • Tampa, Florida + 12 more

Conditions: Hepatic Impairment
Interventions: GBT440; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Epilepsy
Interventions: NeuroBlate System; Device
Lead sponsor: Monteris Medical; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: Phoenix, Arizona • New Haven, Connecticut • Kansas City, Kansas + 2 more

Conditions: Healthy
Interventions: Finasteride; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Atopic Dermatitis
Interventions: tralokinumab; Drug
Lead sponsor: Psoriasis Treatment Center of Central New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: East Windsor, New Jersey

Search by objective public record fields.

Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme

A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS

Remote Methadone Ingestion Surveillance Trial (RMIST)

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants

Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation

A Comparative Study to Assess the Prevention of Surgical Site Infection (SSI's) in Revision Total Joint Arthroplasty Patients Treated With Single-Use Negative Pressure Wound Therapy (PICO™) or Standard Care Dressings (AQUACEL® Ag SURGICAL Dressing)

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist

Measurement of Insulin Levels in the Cerebrospinal Fluid of Healthy Adults After a Single Intranasal Dose - Middle Age

Evaluation of MoodRing on Improving the Quality of Depression Management in Adolescents

Pain Management Protocol for Pediatric Sickle Cell Disease

Lead Migration During the Spinal Cord Stimulation Trial Period and Therapeutic Response

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers

Minimizing Reperfusion Injury in Patients With Acute Myocardial Infarction

Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1

SDF Application in Oral Cancer Patients to Prevent Dental Caries

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment

Feasibility Study on LITT for Medical Refractory Epilepsy

Bioequivalence Study of Finasteride 5 mg Tablet Formulations Under Fasting Conditions

Tralokinumab for Dupilumab Failures